{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:50:35Z","timestamp":1790653835204,"version":"4.1.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Akcea Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing the ongoing coronavirus disease 2019 (COVID-19) pandemic has raised serious concern for patients with chronic disease. A correlation has been identified between the severity of COVID-19 and a patient\u2019s preexisting comorbidities. Although COVID-19 primarily involves the respiratory system, dysfunction in multiple organ systems is common, particularly in the cardiovascular, gastrointestinal, immune, renal, and nervous systems. Patients with amyloid transthyretin (ATTR) amyloidosis represent a population particularly vulnerable to COVID-19 morbidity due to the multisystem nature of ATTR amyloidosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main body<\/jats:title><jats:p>ATTR amyloidosis is a clinically heterogeneous progressive disease, resulting from the accumulation of amyloid fibrils in various organs and tissues. Amyloid deposition causes multisystem clinical manifestations, including cardiomyopathy and polyneuropathy, along with gastrointestinal symptoms and renal dysfunction. Given the potential for exacerbation of organ dysfunction, physicians note possible unique challenges in the management of patients with ATTR amyloidosis who develop multiorgan complications from COVID-19. While the interplay between COVID-19 and ATTR amyloidosis is still being evaluated, physicians should consider that the heightened susceptibility of patients with ATTR amyloidosis to multiorgan complications might increase their risk for poor outcomes with COVID-19.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with ATTR amyloidosis are suspected to have a higher risk of morbidity and mortality due to age and underlying ATTR amyloidosis-related organ dysfunction. While further research is needed to characterize this risk and management implications, ATTR amyloidosis patients might require specialized management if they develop COVID-19. The risks of delaying diagnosis or interrupting treatment for patients with ATTR amyloidosis should be balanced with the risk of exposure in the health care setting. Both physicians and patients must adapt to a new construct for care during and possibly after the pandemic to ensure optimal health for patients with ATTR amyloidosis, minimizing treatment interruptions.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13023-021-01834-0","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T10:03:39Z","timestamp":1620295419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable"],"prefix":"10.1186","volume":"16","author":[{"suffix":"III","given":"Thomas H.","family":"Brannagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Auer-Grumbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Briani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Drachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowell","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna K.","family":"Gaggin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami L.","family":"Khella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Nativi-Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemi","family":"Olugemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut H.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Waddington-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6424-4413","authenticated-orcid":false,"given":"Frederick L.","family":"Ruberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"1834_CR1","doi-asserted-by":"publisher","first-page":"101623","DOI":"10.1016\/j.tmaid.2020.101623","volume":"34","author":"AJ Rodriguez-Morales","year":"2020","unstructured":"Rodriguez-Morales AJ, Cardona-Ospina JA, Guti\u00e9rrez-Ocampo E, Villamizar-Pe\u00f1a R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.","journal-title":"Travel Med Infect Dis"},{"issue":"7","key":"1834_CR2","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.18632\/aging.103000","volume":"12","author":"B Wang","year":"2020","unstructured":"Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049\u201357.","journal-title":"Aging (Albany NY)"},{"key":"1834_CR3","doi-asserted-by":"publisher","first-page":"m1966","DOI":"10.1136\/bmj.m1966","volume":"369","author":"CM Petrilli","year":"2020","unstructured":"Petrilli CM, Jones SA, Yang J, Rajagopalan H, O\u2019Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.","journal-title":"BMJ"},{"key":"1834_CR4","doi-asserted-by":"crossref","unstructured":"Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2020.","DOI":"10.1002\/jmv.26424"},{"issue":"10223","key":"1834_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395(10223):497\u2013506.","journal-title":"China Lancet"},{"key":"1834_CR6","doi-asserted-by":"publisher","first-page":"175628482093462","DOI":"10.1177\/1756284820934626","volume":"13","author":"S Su","year":"2020","unstructured":"Su S, Shen J, Zhu L, Qiu Y, He JS, Tan JY, et al. Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therap Adv Gastroenterol. 2020;13:1756284820934626.","journal-title":"Therap Adv Gastroenterol"},{"issue":"18","key":"1834_CR7","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708\u201320.","journal-title":"N Engl J Med"},{"issue":"9","key":"1834_CR8","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1093\/gerona\/glaa146","volume":"75","author":"L Palmieri","year":"2020","unstructured":"Palmieri L, Vanacore N, Donfrancesco C, Lo Noce C, Canevelli M, Punzo O, et al. Clinical characteristics of hospitalized individuals dying with COVID-19 by age group in Italy. J Gerontol A Biol Sci Med Sci. 2020;75(9):1796\u2013800.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"1834_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S2468-1253(20)30126-6","volume":"5","author":"R Mao","year":"2020","unstructured":"Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667\u201378.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"1834_CR10","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420\u20132.","journal-title":"Lancet Respir Med"},{"issue":"20","key":"1834_CR11","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.120.046941","volume":"141","author":"KJ Clerkin","year":"2020","unstructured":"Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648\u201355.","journal-title":"Circulation"},{"key":"1834_CR12","doi-asserted-by":"publisher","first-page":"116884","DOI":"10.1016\/j.jns.2020.116884","volume":"414","author":"GC Rom\u00e1n","year":"2020","unstructured":"Rom\u00e1n GC, Spencer PS, Reis J, Buguet A, Faris MEA, Katrak SM, et al. The neurology of COVID-19 revisited: a proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries. J Neurol Sci. 2020;414:116884.","journal-title":"J Neurol Sci"},{"issue":"3","key":"1834_CR13","first-page":"2344","volume":"20","author":"IA Tanasa","year":"2020","unstructured":"Tanasa IA, Manciuc C, Carauleanu A, Navolan DB, Bohiltea RE, Nemescu D. Anosmia and ageusia associated with coronavirus infection (COVID-19)\u2014What is known? Exp Ther Med. 2020;20(3):2344\u20137.","journal-title":"Exp Ther Med"},{"key":"1834_CR14","doi-asserted-by":"crossref","unstructured":"Zeng JH, Wu WB, Qu JX, Wang Y, Dong CF, Luo YF, et al. Cardiac manifestations of COVID-19 in Shenzhen, China. Infection. 2020:1\u201310.","DOI":"10.1007\/s15010-020-01473-w"},{"issue":"23","key":"1834_CR15","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood.2020006000","volume":"135","author":"JM Connors","year":"2020","unstructured":"Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033\u201340.","journal-title":"Blood"},{"key":"1834_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cytogfr.2020.05.003","volume":"53","author":"F Coperchini","year":"2020","unstructured":"Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine\/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25\u201332.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"1834_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","volume":"164","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164(2):222-8.e1.","journal-title":"Am Heart J"},{"issue":"3","key":"1834_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","volume":"133","author":"LH Connors","year":"2016","unstructured":"Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016;133(3):282\u201390.","journal-title":"Circulation"},{"issue":"2","key":"1834_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","volume":"22","author":"PL Swiecicki","year":"2015","unstructured":"Swiecicki PL, Zhen DB, Mauermann ML, Kyle RA, Zeldenrust SR, Grogan M, et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid. 2015;22(2):123\u201331.","journal-title":"Amyloid"},{"key":"1834_CR20","unstructured":"Azevedo EP, Foguel D. The role of inflammation in amyloid diseases. Amyloid Diseases. London, UK: IntechOpen; 2018."},{"issue":"1","key":"1834_CR21","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/s41598-017-01775-4","volume":"7","author":"G Suenaga","year":"2017","unstructured":"Suenaga G, Ikeda T, Masuda T, Motokawa H, Yamashita T, Takamatsu K, et al. Inflammatory state exists in familial amyloid polyneuropathy that may be triggered by mutated transthyretin. Sci Rep. 2017;7(1):1579.","journal-title":"Sci Rep"},{"issue":"11","key":"1834_CR22","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.7150\/thno.14584","volume":"6","author":"SM Kurian","year":"2016","unstructured":"Kurian SM, Novais M, Whisenant T, Gelbart T, Buxbaum JN, Kelly JW, et al. Peripheral blood cell gene expression diagnostic for identifying symptomatic transthyretin amyloidosis patients: male and female specific signatures. Theranostics. 2016;6(11):1792\u2013809.","journal-title":"Theranostics"},{"issue":"2","key":"1834_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/13506129.2019.1698417","volume":"27","author":"E Driggin","year":"2020","unstructured":"Driggin E, Helmke S, De Los SJ, Teruya S, Guadalupe S, Goldsmith J, et al. Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: association with outcomes and the clinical phenotype. Amyloid. 2020;27(2):73\u201380.","journal-title":"Amyloid"},{"issue":"2","key":"1834_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40120-020-00210-7","volume":"9","author":"H Koike","year":"2020","unstructured":"Koike H, Katsuno M. Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol Ther. 2020;9(2):317\u201333.","journal-title":"Neurol Ther"},{"issue":"9","key":"1834_CR25","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1073\/pnas.75.9.4499","volume":"75","author":"PP Costa","year":"1978","unstructured":"Costa PP, Figueira AS, Bravo FR. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA. 1978;75(9):4499\u2013503.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1834_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Conceicao","year":"2016","unstructured":"Conceicao I, Gonzalez-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, et al. \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5\u20139.","journal-title":"J Peripher Nerv Syst"},{"issue":"2\u20133","key":"1834_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0014-5793(01)02480-2","volume":"498","author":"MJ Saraiva","year":"2001","unstructured":"Saraiva MJ. Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett. 2001;498(2\u20133):201\u20133.","journal-title":"FEBS Lett"},{"issue":"13","key":"1834_CR28","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1021\/acs.biochem.6b00164","volume":"55","author":"KH Lim","year":"2016","unstructured":"Lim KH, Dasari AK, Hung I, Gan Z, Kelly JW, Wemmer DE. Structural changes associated with transthyretin misfolding and amyloid formation revealed by solution and solid-state NMR. Biochemistry. 2016;55(13):1941\u20134.","journal-title":"Biochemistry"},{"issue":"1","key":"1834_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63\u201376.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1834_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1834_CR31","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jhsa.2019.06.016","volume":"44","author":"JP Donnelly","year":"2019","unstructured":"Donnelly JP, Hanna M, Sperry BW, Seitz WH Jr. Carpal tunnel syndrome: A potential early, red-flag sign of amyloidosis. J Hand Surg Am. 2019;44(10):868\u201376.","journal-title":"J Hand Surg Am"},{"issue":"7","key":"1834_CR32","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520\u20138.","journal-title":"Eur Heart J"},{"issue":"9","key":"1834_CR33","doi-asserted-by":"publisher","first-page":"E2403","DOI":"10.1002\/humu.22619","volume":"35","author":"DM Rowczenio","year":"2014","unstructured":"Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35(9):E2403\u201312.","journal-title":"Hum Mutat"},{"key":"1834_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1834_CR35","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","volume":"83","author":"H Koike","year":"2012","unstructured":"Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry. 2012;83(2):152\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"1834_CR36","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014\u201320.","journal-title":"J Am Coll Cardiol"},{"key":"1834_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09688-0","author":"D Adams","year":"2020","unstructured":"Adams D, Ando Y, Beirao JM, Coelho T, Gertz MA, Gillmore JD, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2020. https:\/\/doi.org\/10.1007\/s00415-019-09688-0.","journal-title":"J Neurol"},{"issue":"9","key":"1834_CR38","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","volume":"33","author":"PT Sattianayagam","year":"2012","unstructured":"Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33(9):1120\u20137.","journal-title":"Eur Heart J"},{"issue":"11","key":"1834_CR39","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","volume":"59","author":"H Koike","year":"2002","unstructured":"Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol. 2002;59(11):1771\u20136.","journal-title":"Arch Neurol"},{"issue":"21","key":"1834_CR40","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451\u201366.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1834_CR41","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","volume":"77","author":"L Mao","year":"2020","unstructured":"Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. China JAMA Neurol. 2020;77(6):683\u201390.","journal-title":"China JAMA Neurol"},{"issue":"9","key":"1834_CR42","first-page":"311","volume":"70","author":"FJ Carod-Artal","year":"2020","unstructured":"Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Rev Neurol. 2020;70(9):311\u201322.","journal-title":"Rev Neurol"},{"issue":"7","key":"1834_CR43","first-page":"e910","volume":"95","author":"A Benussi","year":"2020","unstructured":"Benussi A, Pilotto A, Premi E, Libri I, Giunta M, Agosti C, et al. Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy. Italy Neurol. 2020;95(7):e910\u201320.","journal-title":"Italy Neurol"},{"issue":"2","key":"1834_CR44","doi-asserted-by":"publisher","first-page":"1602313","DOI":"10.1183\/13993003.02313-2016","volume":"49","author":"K Ussavarungsi","year":"2017","unstructured":"Ussavarungsi K, Yi ES, Maleszewski JJ, Kurtin PJ, Dasari S, Theis JD, et al. Clinical relevance of pulmonary amyloidosis: an analysis of 76 autopsy-derived cases. Eur Respir J. 2017;49(2):1602313.","journal-title":"Eur Respir J"},{"key":"1834_CR45","doi-asserted-by":"crossref","unstructured":"Smith RR, Hutchins GM, Moore GW, Humphrey RL. Type and distribution of pulmonary parenchymal and vascular amyloid. Correlation with cardiac amyloid. Am J Med. 1979;66(1):96\u2013104.","DOI":"10.1016\/0002-9343(79)90488-1"},{"issue":"145","key":"1834_CR46","doi-asserted-by":"publisher","first-page":"170046","DOI":"10.1183\/16000617.0046-2017","volume":"26","author":"P Milani","year":"2017","unstructured":"Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G. The lung in amyloidosis. Eur Respir Rev. 2017;26(145):170046.","journal-title":"Eur Respir Rev"},{"key":"1834_CR47","doi-asserted-by":"crossref","unstructured":"Utz JP, Swensen SJ, Gertz MA. Pulmonary amyloidosis. The Mayo Clinic experience from 1980 to 1993. Ann Intern Med. 1996;124(4):407\u201313.","DOI":"10.7326\/0003-4819-124-4-199602150-00004"},{"key":"1834_CR48","doi-asserted-by":"crossref","unstructured":"Polak SB, Van Gool IC, Cohen D, von der Th\u00fcsen JH, van Paassen J. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol. 2020: 2128\u20132138.","DOI":"10.1038\/s41379-020-0603-3"},{"issue":"10","key":"1834_CR49","doi-asserted-by":"publisher","first-page":"2243.e5","DOI":"10.1016\/j.ajem.2020.05.044","volume":"38","author":"RG Wilkerson","year":"2020","unstructured":"Wilkerson RG, Adler JD, Shah NG, Brown R. Silent hypoxia: a harbinger of clinical deterioration in patients with COVID-19. Am J Emerg Med. 2020;38(10):2243.e5-2243.e6.","journal-title":"Am J Emerg Med"},{"key":"1834_CR50","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ijid.2020.07.014","volume":"99","author":"NJU Fuglebjerg","year":"2020","unstructured":"Fuglebjerg NJU, Jensen TO, Hoyer N, Ryrs\u00f8 CK, Lindegaard B, Barrella HZ. Silent hypoxia in patients with SARS CoV-2 infection before hospital discharge. Int J Infect Dis. 2020;99:100\u20131.","journal-title":"Int J Infect Dis"},{"key":"1834_CR51","doi-asserted-by":"crossref","unstructured":"Ottestad W, Seim M, M\u00e6hlen JO. COVID-19 with silent hypoxemia. Tidsskr Nor Laegeforen. 2020;140(7).","DOI":"10.4045\/tidsskr.20.0299"},{"key":"1834_CR52","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"The RECOVERY Collaborative Group","year":"2021","unstructured":"The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693\u2013704.","journal-title":"N Engl J Med"},{"issue":"4","key":"1834_CR53","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jaad.2020.06.1016","volume":"83","author":"EE Freeman","year":"2020","unstructured":"Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Desai SR, et al. The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020;83(4):1118\u201329.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1834_CR54","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2020.05.109","volume":"83","author":"EE Freeman","year":"2020","unstructured":"Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Takeshita J, et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. J Am Acad Dermatol. 2020;83(2):486\u201392.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1834_CR55","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bjd.19163","volume":"183","author":"C Galv\u00e1n Casas","year":"2020","unstructured":"Galv\u00e1n Casas C, Catal\u00e0 A, Carretero Hern\u00e1ndez G, Rodr\u00edguez-Jim\u00e9nez P, Fern\u00e1ndez-Nieto D, Rodr\u00edguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71\u20137.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1834_CR56","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","volume":"73","author":"EA El-Am","year":"2019","unstructured":"El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, et al. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol. 2019;73(5):589\u201397.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1834_CR57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/TP.0000000000003523","volume":"105","author":"Y Azzi","year":"2021","unstructured":"Azzi Y, Bartash R, Scalea J, Loarte-Campos P, Akalin E. COVID-19 and solid organ transplantation: a review article. Transplantation. 2021;105(1):37\u201355.","journal-title":"Transplantation"},{"issue":"1","key":"1834_CR58","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/TP.0000000000003536","volume":"105","author":"M Zaidan","year":"2021","unstructured":"Zaidan M, Legendre C. Solid organ transplantation in the era of COVID-19: lessons from France. Transplantation. 2021;105(1):61\u20136.","journal-title":"Transplantation"},{"issue":"6","key":"1834_CR59","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1002\/hep.31574","volume":"72","author":"A Rabiee","year":"2020","unstructured":"Rabiee A, Sadowski B, Adeniji N, Perumalswami PV, Nguyen V, Moghe A, et al. Liver Injury in liver transplant recipients with coronavirus disease 2019 (COVID-19): US multicenter experience. Hepatology. 2020;72(6):1900\u201311.","journal-title":"Hepatology"},{"issue":"10","key":"1834_CR60","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1136\/gutjnl-2020-321923","volume":"69","author":"C Becchetti","year":"2020","unstructured":"Becchetti C, Zambelli MF, Pasulo L, Donato MF, Invernizzi F, Detry O, et al. COVID-19 in an international European liver transplant recipient cohort. Gut. 2020;69(10):1832\u201340.","journal-title":"Gut"},{"key":"1834_CR61","doi-asserted-by":"crossref","unstructured":"Stein RA. COVID-19: Risk groups, mechanistic insights and challenges. Int J Clin Pract. 2020:e13512.","DOI":"10.1111\/ijcp.13512"},{"key":"1834_CR62","doi-asserted-by":"publisher","first-page":"107263","DOI":"10.1016\/j.carpath.2020.107263","volume":"49","author":"C Grosse","year":"2020","unstructured":"Grosse C, Grosse A, Salzer HJF, D\u00fcnser MW, Motz R, Langer R. Analysis of cardiopulmonary findings in COVID-19 fatalities: High incidence of pulmonary artery thrombi and acute suppurative bronchopneumonia. Cardiovasc Pathol. 2020;49:107263.","journal-title":"Cardiovasc Pathol"},{"issue":"2","key":"1834_CR63","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.amjcard.2011.03.040","volume":"108","author":"MD Benson","year":"2011","unstructured":"Benson MD, Teague SD, Kovacs R, Feigenbaum H, Jung J, Kincaid JC. Rate of progression of transthyretin amyloidosis. Am J Cardiol. 2011;108(2):285\u20139.","journal-title":"Am J Cardiol"},{"issue":"22","key":"1834_CR64","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1834_CR65","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/heartjnl-2015-308657","volume":"102","author":"A Senapati","year":"2016","unstructured":"Senapati A, Sperry BW, Grodin JL, Kusunose K, Thavendiranathan P, Jaber W, et al. Prognostic implication of relative regional strain ratio in cardiac amyloidosis. Heart. 2016;102(10):748\u201354.","journal-title":"Heart"},{"issue":"10","key":"1834_CR66","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1161\/CIRCRESAHA.120.317055","volume":"126","author":"A Akhmerov","year":"2020","unstructured":"Akhmerov A, Marb\u00e1n E. COVID-19 and the heart. Circ Res. 2020;126(10):1443\u201355.","journal-title":"Circ Res"},{"issue":"1","key":"1834_CR67","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.chest.2017.02.019","volume":"152","author":"V Zochios","year":"2017","unstructured":"Zochios V, Parhar K, Tunnicliffe W, Roscoe A, Gao F. The right ventricle in ARDS. Chest. 2017;152(1):181\u201393.","journal-title":"Chest"},{"issue":"4","key":"1834_CR68","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00059-020-04931-1","volume":"45","author":"H Thiele","year":"2020","unstructured":"Thiele H. Cardiovascular emergencies in the COVID-19 pandemic. Herz. 2020;45(4):327\u20138.","journal-title":"Herz"},{"issue":"24","key":"1834_CR69","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1001\/jama.2020.23422","volume":"324","author":"G Piazza","year":"2020","unstructured":"Piazza G, Morrow DA. Diagnosis, management, and pathophysiology of arterial and venous thrombosis in COVID-19. JAMA. 2020;324(24):2548\u20139.","journal-title":"JAMA"},{"key":"1834_CR70","doi-asserted-by":"crossref","unstructured":"Dyck PJ, Lambert EH. Dissociated sensation in amylidosis. Compound action potential, quantitative histologic and teased-fiber, and electron microscopic studies of sural nerve biopsies. Arch Neurol. 1969;20(5):490\u2013507.","DOI":"10.1001\/archneur.1969.00480110054005"},{"issue":"3","key":"1834_CR71","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.21332","volume":"40","author":"DH Kim","year":"2009","unstructured":"Kim DH, Zeldenrust SR, Low PA, Dyck PJ. Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy. Muscle Nerve. 2009;40(3):363\u201370.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1834_CR72","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/mus.25257","volume":"55","author":"T Coelho","year":"2017","unstructured":"Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR. Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2017;55(3):323\u201332.","journal-title":"Muscle Nerve"},{"issue":"6","key":"1834_CR73","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/jnnp-2015-310907","volume":"87","author":"AS Carr","year":"2016","unstructured":"Carr AS, Pelayo-Negro AL, Evans MR, Laura M, Blake J, Stancanelli C, et al. A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. J Neurol Neurosurg Psychiatry. 2016;87(6):620\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1834_CR74","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/1756285612470192","volume":"6","author":"D Adams","year":"2013","unstructured":"Adams D. Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord. 2013;6(2):129\u201339.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"1834_CR75","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/ane.13266","volume":"142","author":"A Whittaker","year":"2020","unstructured":"Whittaker A, Anson M, Harky A. Neurological Manifestations of COVID-19: a systematic review and current update. Acta Neurol Scand. 2020;142(1):1422.","journal-title":"Acta Neurol Scand"},{"key":"1834_CR76","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3389\/fneur.2020.00805","volume":"11","author":"S Radmard","year":"2020","unstructured":"Radmard S, Epstein SE, Roeder HJ, Michalak AJ, Shapiro SD, Boehme A, et al. Inpatient neurology consultations during the onset of the SARS-CoV-2 New York City pandemic: a single center case series. Front Neurol. 2020;11:805.","journal-title":"Front Neurol"},{"issue":"9","key":"1834_CR77","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/STROKEAHA.120.031208","volume":"51","author":"G Ntaios","year":"2020","unstructured":"Ntaios G, Michel P, Georgiopoulos G, Guo Y, Li W, Xiong J, et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry. Stroke. 2020;51(9):e254\u20138.","journal-title":"Stroke"},{"issue":"5","key":"1834_CR78","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10072-020-04375-9","volume":"41","author":"C Baracchini","year":"2020","unstructured":"Baracchini C, Pieroni A, Viaro F, Cianci V, Cattelan AM, Tiberio I, et al. Acute stroke management pathway during Coronavirus-19 pandemic. Neurol Sci. 2020;41(5):1003\u20135.","journal-title":"Neurol Sci"},{"issue":"2","key":"1834_CR79","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/jns.12382","volume":"25","author":"E Scheidl","year":"2020","unstructured":"Scheidl E, Canseco DD, Hadji-Naumov A, Bereznai B. Guillain\u2013Barr\u00e9 syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature. J Peripher Nerv Syst. 2020;25(2):204\u20137.","journal-title":"J Peripher Nerv Syst"},{"key":"1834_CR80","doi-asserted-by":"publisher","first-page":"e00815","DOI":"10.1016\/j.idcr.2020.e00815","volume":"21","author":"F Ghiasvand","year":"2020","unstructured":"Ghiasvand F, Ghadimi M, Ghadimi F, Safarpour S, Hosseinzadeh R, SeyedAlinaghi S. Symmetrical polyneuropathy in coronavirus disease 2019 (COVID-19). IDCases. 2020;21:e00815.","journal-title":"IDCases"},{"issue":"11","key":"1834_CR81","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1111\/ene.14444","volume":"27","author":"M Luigetti","year":"2020","unstructured":"Luigetti M, Iorio R, Bentivoglio AR, Tricoli L, Riso V, Marotta J, et al. Assessment of neurological manifestations in hospitalized patients with COVID-19. Eur J Neurol. 2020;27(11):2322\u20138.","journal-title":"Eur J Neurol"},{"issue":"2","key":"1834_CR82","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10072-020-04553-9","volume":"42","author":"E Agosti","year":"2020","unstructured":"Agosti E, Giorgianni A, D\u2019Amore F, Vinacci G, Balbi S, Locatelli D. Is Guillain\u2013Barr\u00e8 syndrome triggered by SARS-CoV-2? Case report and literature review. Neurol Sci. 2020;42(2):607\u201312.","journal-title":"Neurol Sci"},{"issue":"4","key":"1834_CR83","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00415-020-09911-3","volume":"268","author":"GL Gigli","year":"2021","unstructured":"Gigli GL, Bax F, Marini A, Pellitteri G, Scalise A, Surcinelli A, et al. Guillain\u2013Barr\u00e9 syndrome in the COVID-19 era: just an occasional cluster? J Neurol. 2021;268(4):1195\u20137.","journal-title":"J Neurol"},{"issue":"2","key":"1834_CR84","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/brain\/awaa433","volume":"144","author":"S Keddie","year":"2020","unstructured":"Keddie S, Pakpoor J, Mousele C, Pipis M, Machado PM, Foster M, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain\u2013Barr\u00e9 syndrome. Brain. 2020;144(2):682\u201393.","journal-title":"Brain"},{"key":"1834_CR85","doi-asserted-by":"publisher","unstructured":"Needham E, Newcombe V, Michell A, Thornton R, Grainger A, Anwar F, et al. Mononeuritis multiplex: an unexpectedly frequent feature of severe COVID-19. J Neurol. 2020. https:\/\/doi.org\/10.1007\/s00415-020-10321-8.","DOI":"10.1007\/s00415-020-10321-8"},{"key":"1834_CR86","doi-asserted-by":"crossref","unstructured":"Carberry N, Badu H, Ulane CM, Beckley A, Rosenberg SJ, Brenner K, et al. Mononeuropathy multiplex following COVID-19. J Clin Neuromuscul Dis. 2021.","DOI":"10.1097\/CND.0000000000000367"},{"issue":"3","key":"1834_CR87","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1152\/physrev.00028.2014","volume":"95","author":"O Friedrich","year":"2015","unstructured":"Friedrich O, Reid MB, Van den Berghe G, Vanhorebeek I, Hermans G, Rich MM, et al. The sick and the weak: neuropathies\/myopathies in the critically ill. Physiol Rev. 2015;95(3):1025\u2013109.","journal-title":"Physiol Rev"},{"issue":"3","key":"1834_CR88","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/jnnp.2009.192997","volume":"82","author":"S Koch","year":"2011","unstructured":"Koch S, Spuler S, Deja M, Bierbrauer J, Dimroth A, Behse F, et al. Critical illness myopathy is frequent: accompanying neuropathy protracts ICU discharge. J Neurol Neurosurg Psychiatry. 2011;82(3):287\u201393.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"1834_CR89","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nrneurol.2009.75","volume":"5","author":"W Zink","year":"2009","unstructured":"Zink W, Kollmar R, Schwab S. Critical illness polyneuropathy and myopathy in the intensive care unit. Nat Rev Neurol. 2009;5(7):372\u20139.","journal-title":"Nat Rev Neurol"},{"key":"1834_CR90","doi-asserted-by":"crossref","unstructured":"Carda S, Invernizzi M, Bavikatte G, Bensma\u00efl D, Bianchi F, Deltombe T, et al. COVID-19 pandemic. What should PRM specialists do? A clinician's perspective. Eur J Phys Rehabil Med. 2020;56(4):515\u201324.","DOI":"10.23736\/S1973-9087.20.06317-0"},{"key":"1834_CR91","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1750-1172-9-61","volume":"9","author":"J Wixner","year":"2014","unstructured":"Wixner J, Mundayat R, Karayal ON, Anan I, Karling P, Suhr OB, et al. THAOS: gastrointestinal manifestations of transthyretin amyloidosis\u2014common complications of a rare disease. Orphanet J Rare Dis. 2014;9:61.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1834_CR92","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1053\/j.gastro.2020.04.017","volume":"159","author":"YR Nobel","year":"2020","unstructured":"Nobel YR, Phipps M, Zucker J, Lebwohl B, Wang TC, Sobieszczyk ME, et al. Gastrointestinal symptoms and coronavirus disease 2019: a case-control study from the United States. Gastroenterology. 2020;159(1):373-5.e2.","journal-title":"Gastroenterology"},{"issue":"5","key":"1834_CR93","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000507305","volume":"144","author":"L Perico","year":"2020","unstructured":"Perico L, Benigni A, Remuzzi G. Should COVID-19 concern nephrologists? why and to what extent? the emerging impasse of angiotensin blockade. Nephron. 2020;144(5):213\u201321.","journal-title":"Nephron"},{"issue":"7","key":"1834_CR94","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S2213-2600(20)30229-0","volume":"8","author":"C Ronco","year":"2020","unstructured":"Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 2020;8(7):738\u201342.","journal-title":"Lancet Respir Med"},{"key":"1834_CR95","doi-asserted-by":"publisher","unstructured":"Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. Caution on Kidney Dysfunctions of COVID-19 Patients MedRXiv: Cold Spring Harbor Press; 2020 (updated March 27, 2020). https:\/\/www.medrxiv.org\/content\/https:\/\/doi.org\/10.1101\/2020.02.08.20021212v2.","DOI":"10.1101\/2020.02.08.20021212v2"},{"issue":"1","key":"1834_CR96","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.kint.2020.04.003","volume":"98","author":"H Su","year":"2020","unstructured":"Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98(1):219\u201327.","journal-title":"Kidney Int"},{"issue":"4","key":"1834_CR97","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00415-019-09671-9","volume":"267","author":"T Coelho","year":"2020","unstructured":"Coelho T, Yarlas A, Waddington-Cruz M, White MK, Sikora Kessler A, Lovley A, et al. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. J Neurol. 2020;267(4):1070\u20139.","journal-title":"J Neurol"},{"issue":"1","key":"1834_CR98","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"1834_CR99","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22\u201331.","journal-title":"N Engl J Med"},{"issue":"11","key":"1834_CR100","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"issue":"3","key":"1834_CR101","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","volume":"27","author":"L Obici","year":"2020","unstructured":"Obici L, Berk JL, Gonzalez-Duarte A, Coelho T, Gillmore J, Schmidt HH, et al. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2020;27(3):153\u201362.","journal-title":"Amyloid"},{"key":"1834_CR102","unstructured":"International Society for Amyloidosis. International Society of Amyloidosis recommendations on the management of patients with systemic amyloidosis during the COVID-19 pandemic: International Society for Amyloidosis; 2020 (updated April 20, 2020)."},{"issue":"4","key":"1834_CR103","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/13506129.2017.1375908","volume":"24","author":"J Rubin","year":"2017","unstructured":"Rubin J, Alvarez J, Teruya S, Castano A, Lehman RA, Weidenbaum M, et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? Amyloid. 2017;24(4):226\u201330.","journal-title":"Amyloid"},{"issue":"9","key":"1834_CR104","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.humpath.2010.11.017","volume":"42","author":"T Sueyoshi","year":"2011","unstructured":"Sueyoshi T, Ueda M, Jono H, Irie H, Sei A, Ide J, et al. Wild-type transthyretin-derived amyloidosis in various ligaments and tendons. Hum Pathol. 2011;42(9):1259\u201364.","journal-title":"Hum Pathol"},{"issue":"2","key":"1834_CR105","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13365-020-00840-5","volume":"26","author":"JR Berger","year":"2020","unstructured":"Berger JR. COVID-19 and the nervous system. J Neurovirol. 2020;26(2):143\u20138.","journal-title":"J Neurovirol"},{"issue":"9","key":"1834_CR106","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S1474-4422(20)30221-0","volume":"19","author":"MA Ellul","year":"2020","unstructured":"Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767\u201383.","journal-title":"Lancet Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01834-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01834-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01834-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T13:23:58Z","timestamp":1672061038000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01834-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1834"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01834-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"22 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Michaela Auer-Grumbach: Speaker honoraria from Pfizer, Akcea Therapeutics, Biogen, Sanofi-Genzyme, Roche, CSL Behring and Novartis; Scientific Advisory Board participation with Akcea Therapeutics, Biogen, Sanofi-Genzyme, Roche, CSL Behring and Novartis; Research support from Pfizer, Biogen, Sanofi-Genzyme and Roche. John L. Berk: Consulting honoraria from Alnylam Pharmaceutical, Akcea Therapeutics, Ionis Pharmaceutical, and Scientific Advisory Board participation with Intellia Therapeutics and Corino Therapeutics. Thomas H Brannagan III: Consulting income from Akcea, Alnylam, Ionis, and Pfizer; institution has received clinical trial funding from Alnylam and Ionis. Chiara Briani: Speaker and consulting honoraria from Akcea, Alnylam, and Pfizer and travel grants from Kedrion, Alnylam, and CSL Behring. Vera Bril: Consultant for CSL, Grifols, Octapharma, UCB, Argenx, Takeda, Alnylam, Ionis, Akcea, Alexion, Immunovant, and Momenta, and Sanofi; research support: CSL, Grifols, Octapharma, UCB, Argenx, Takeda, Ionis, Akcea, Alexion, Immunovant, and Momentaand Sanofi. Teresa Coelho: Speaker and consultant honoraria and financial support to attend scientific meetings from Pfizer, Alnylam, Ionis, Akcea, Biogen and Prothena. Institution received clinical trial and research funding from Pfizer, Alnylam, Ionis, Prothena and Eidos. Thibaud Damy: Consulting honoraria and research support from Akcea, Alnylam, Neurimmune and Pfizer. Angela Dispenzieri: Trial support: Pfizer, Alnylam, Takeda, and Celgene; advisory board: Akcea, Janssen. Brian M. Drachman: Consulting\/advisory board member for Eidos and Alnylam. Nowell Fine: Consulting honoraria and research support from Akcea Alnylam and Pfizer. Hanna K. Gaggin: Research grant support from Roche Diagnostics, Jana Care, Ortho Clinical, Novartis, Pfizer, Alnylam, and Akcea; consulting income from Amgen, Eko, Merck, Roche Diagnostics, Radiometer, and Pfizer; stock ownership for Eko; research payments for clinical endpoint committees from Radiometer. She has also received research payment for clinical endpoint committees from Baim Institute for Clinical Research for Abbott, Siemens, and Beckman Coulter. Morie Gertz: Personal fees from Ionis\/Akcea, Alnylam, Prothena, Janssen, Annexon, Appellis, Amgen, Medscape, Physician\u2019s Education Research, Data Safety Monitoring board from AbbVie and Celgene, Research to Practice, workforce training Sanofi; grants and personal fees from Spectrum; speaker fees from Teva, Johnson and Johnson, Medscape, DAVA oncology; advisory board for Pharmacyclics, Proclara; Development of educational materials for i3Health; Educational Program development for i3Health Royalties from Springer Publishing; Grant Funding Amyloidosis Foundation; International Waldenstrom Foundation; NCI SPORE MM SPORE 5P50 CA186781-04; and stock options for Aurora Bio. Julian D. Gillmore: Advisory Board member for Alnylam, Akcea, Eidos, and Pfizer. Esther Gonzalez: Speaking fees from Pfizer and Alnylam. Consulting fees from Pfizer, Akcea Therapeutics and Proclara. Research support to her institution from Pfizer, Eidos, and Alnylam. Mazen Hanna: Advisory board for Pfizer, Eidos, Akcea and Alnylam. David R. Hurwitz: Employee of Akcea Therapeutics. Sami L. Khella: Consultant for Eidos and Pfizer. Mathew S. Maurer: Reports grant support from National Institutes of Health [R01HL139671-01], [R21AG058348] and [K24AG036778]; consulting income from Pfizer, GSK, Eidos, Prothena, Akcea, and Alnylam; institution received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam. Jose Nativi-Nicolau: Institution received funding for clinical trials for Pfizer, Akcea, and Eidos and Educational Grants from Pfizer; consultant for Pfizer, Eidos, Akcea, and Alnylam. Kemi Olugemo: Employee of Akcea Therapeutics. Luis F. Quintana: Nothing to disclose. Andrew M. Rosen: Employee of Akcea Therapeutics. Hartmut H. Schmidt: Nothing to disclose. Jacqueline Shehata: Employee of Akcea Therapeutics. Marcia Waddington-Cruz: Received honorarium from NHI, Prothena, FoldRx, Ionis, Pfizer, Alnylam, PTC and Genzyme for travel expenses related to presentations at medical meetings, for acting as a principal investigator in clinical trials and as a consultant member. Carol Whelan: Advisory board member Alnylam and Akcea. Frederick L. Ruberg: Research support from NIH (HL139671), Pfizer, Eidos Therapeutics, and Akcea Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"204"}}